



COMPETITIVE TECHNOLOGIES
Unlocking the Potential of Innovation®

NYSE Amex: CTT	12/14/09
Share Price:	\$2.00
Price Range (52 weeks)	\$ 0.54 – 2.84
Approx. Shares Outstanding:	10.1 million
Website:	www.competitivetech.net

FACT SHEET

- **Corporate Overview** Competitive Technologies, Inc., based in Fairfield, CT, is a global leader in identifying, developing, and commercializing innovative products and technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT provides distribution, patent and technology transfer, selling and licensing services. It focuses on customer needs and matching those needs with commercially viable technology or product solutions provided by its clients.
- **Market** CTT is well positioned to capitalize on factors driving the growth of the innovative product distribution and technology licensing market: the increasing number of new patents, the fast-moving technology market cycle, high cost of R&D, and scarcity of R&D talent. USPTO patent applications have grown to a record-breaking 485,300+ in 2008 from approximately 112,400 in 1980.
- **Strategy** CTT obtains customers' requirements, their wish lists, and leverages its inventory of exclusive products and technologies and its extensive sourcing network to identify and commercialize products and technologies that fulfill unsatisfied needs.

EXECUTIVE MANAGEMENT TEAM

John B. Nano, Chairman, President and CEO
Aris D. Despo, Executive V.P., Business Development
John Rafferty, Vice President and Controller

- **Revenue** CTT earns revenue in two ways, from licensing our clients' and our own technologies to licensees, and in a business model that allows us to share in the profits of distribution of finished products. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. CTT has successfully licensed more than 500 technologies to over 400 individual organizations.
- **Clients and Customers** CTT's activities are global, with recent strong growth in Asia and Europe. CTT's primary focus is directed at developing relationships with customers who have technology or product requirements. CTT continues to nurture and develop relationships with its historical sources, including universities, corporations, independent research institutions and individuals.

CTT is a vital part of the technology commercialization community, and has paid over \$100 million to universities in shared technology revenues.

FINANCIALS (\$000) (Fiscal Year Ends July 31)

	3Mo FY2010	FY2009	FY2008	FY2007	FY2006
Revenues	\$ 143	\$ 348	\$ 1,194	\$ 4,167	\$ 5,188
Expenses and Taxes	899	3,828	7,160	13,061	7,565
Net Income/(Loss)	(756)	(3,480)	(5,966)	(8,894)	(2,377)
Net Income/(Loss) \$/per share *	\$ (0.08)	\$ (0.41)	\$ (0.73)	\$ (1.11)	\$ (0.31)
Shares Outstanding (000) *		8,740	8,156	8,040	7,652
	Oct. 31, 2009	July 31, 2009	July 31, 2008	July 31, 2007	July 31, 2006
Cash/Cash Equiv./Restricted Cash	\$ 545	\$ 752	\$ 2,237	\$ 6,572	\$ 12,909
Other Current Assets	425	406	438	2,792	4,576
Other Assets	471	243	436	349	932
Current/Non-Current Liabilities	1,156	1,116	1,517	2,114	3,963
Shareholders' Equity	285	285	1,594	7,599	14,454

* diluted when applicable

This information should not be construed as an offer to sell or solicitation of an offer to buy Competitive Technologies securities. Statements about our future expectations, are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2009, filed with the SEC on October 27, 2009, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

(over)



DIRECT INQUIRIES TO:

Johnnie D. Johnson, IR Services, LLC, Tel: (860) 434 2465
jdjohnson@corpirservices.com, www.competitivetech.net

- *Technologies* – A portfolio of commercially viable products and technologies exploits opportunities of the paradigm shift resulting from record high costs of both healthcare and energy, with potential to provide solutions in rapidly growing markets:

Pain Management: CTT has worldwide exclusive rights to a non-invasive pain management medical device for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. The device has US FDA clearance for sales in the US, as well as Medical Device CE certification allowing sales throughout Europe and other markets. Country-exclusive distribution agreements have been signed for approximately 50 countries around the world, including the U.S., accounting for over 50% of the world's population. CTT shares in revenue derived from sales to distributors. CTT is reviewing and selecting additional distributors from markets in Europe, Asia and Latin America.

Developed in Italy by CTT's client, Prof. Giuseppe Marineo, the technology was brought to CTT through the efforts of Prof. Giancarlo Elia Valori of the Italian business development group, Sviluppo Lazio S.p.A., and assistance from the Zangani Investor Community™. The multiprocessor apparatus is designed to simultaneously treat multiple pain areas by means of single-use surface electrodes applied to the skin area near the pain. It has successfully been used to treat over 3,000 patients in European hospitals, and dozens of patients in the U.S. CTT licensee GEOMC of Korea manufactures the device commercially for worldwide sales.

Nanotechnology Bone Biomaterial: CTT has exclusive rights to the patented nanoparticle-formulated biomaterial for skeletal bone repair. The flowable, moldable paste forms a solid bone-like structure capable of stabilizing fractured bone within 15 minutes. The technology has superior compressive strength, is machinable and drillable. It can be used for human bones and for dental and veterinary uses. Soteira, Inc. was granted an exclusive license for applications related to the human spine.

Sexual Dysfunction Therapeutic: CTT has exclusive rights to license for development a sexual dysfunction therapeutic. The therapeutic acts on brain receptors to stimulate natural sexual arousal without acting directly on the vascular system, and is effective on both males and females. CTT and XION Corporation have formed a joint venture for the development and commercialization of this technology.

Compressed Air Drying Device: CTT has exclusive North American rights to a patented air-purifying device from SECO Engineering S.r.l. The device eliminates water condensation, oil residues, and solid particles that are contaminants present in compressed air lines, extending the life of pneumatic tools. Applications include aerospace, air-actuated doors, control valves, pneumatic tools, mining and excavation equipment, and processing and packaging machines.

Breast Cancer Test: CTT has rights to the patented breast cancer detection device, Early Breastest™, from the research of Milton Schonberger and Dr. Anthony Barbara. The non-invasive technology generates an analysis that detects angiogenesis, using adhesive pads embedded with hundreds of thermistors, micro-thermometers. The Schonberger patent for the world's first disposable thermometer is the basis for this new technology.

Skin Pigment Enhancer: Clinuvel Pharmaceuticals Ltd. (AUS: CUV) is the exclusive sub-licensee for this sunless-tanning technology being researched as a skin cancer preventative, and therapeutic for vitiligo, albinism and psoriasis. CTT will receive royalties on sales of products using its technology. Orphan Drug Designation has been granted by US FDA.

Lupus Diagnostic and Monitoring Technology: CTT has exclusive worldwide rights to the patented laboratory test developed at the Lahey Clinic to diagnose and monitor Systemic Lupus Erythematosus. This cost-effective, scalable testing platform for early detection of Lupus, which affects approximately 1.5 million patients in the US, monitors therapeutic efficacy and flares.

Encryption Technology: Public key encryption technology that operates at high speeds with low processing and memory requirements. Secure applications include the Internet, telecommunications, smart-cards and e-commerce. NTRUEncrypt™ is accepted for standardization by the Institute of Electrical and Electronics Engineers (IEEE).

Video & Audio Signal Processing – Encoding & Compression: CTT owns rights to two compression technologies in the MPEG LA-administered MPEG-4 Visual Patent Portfolio License Pool, which has nearly 600 licensees. Applications include wireless video conferencing, wired videophones, remote security cameras, medical imaging, and pilot info systems/displays.